首页> 外文期刊>Clinical chemistry and laboratory medicine: CCLM >Long-term prognostic value of midregional pro-adrenomedullin and C-terminal pro-endothelin-1 in patients with acute myocardial infarction.
【24h】

Long-term prognostic value of midregional pro-adrenomedullin and C-terminal pro-endothelin-1 in patients with acute myocardial infarction.

机译:中区肾上腺髓质素和C末端内皮素-1在急性心肌梗死患者中的长期预后价值。

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Background: Midregional pro-adrenomedullin (MR-proADM) and endothelin-1 have been shown to predict mortality of patients with acute myocardial infarction. However, the prognostic value of both biomarkers in predicting long-term clinical events after acute myocardial infarction remains unclear. Methods: In a prospective study, 30 patients suffering from acute ST elevation myocardial infarction or non-ST elevation myocardial infarction were enrolled. Measurements of MR-proADM and CT-pro-endothelin-1 (CT-proET-1) were performed at initial presentation, 2 or 3 days and 4 months after acute myocardial infarction. Long-term clinical events (e.g., recurrent myocardial infarction, percutaneous transluminal coronary angioplasty, aorto-coronary venous bypass or cardiogenic shock) were documented over a period from the 4th until the 10th month. Results: Both MR-proADM and CT-proET-1 were able to differentiate patients with subsequent long-term clinical events (n=11) from those without (n=19). At the timeof acute myocardial infarction, median MR-proADM level of the event group was 0.69 nmol/L as compared to 0.59 nmol/L of the no-event group (p=0.036). A difference was still observed after 3 days (event group median 0.66 nmol/L; no-event group median 0.57 nmol/L; p=0.022). Accordingly, median CT-proET-1 level was 72.9 pmol/L in the event group as compared to a median of 54.4 pmol/L in patients in the no-event group (p=0.009) 3 days after acute myocardial infarction. Within the acute phase, patients with MR-proADM levels >/=0.67 nmol/L were 3 times more likely (relative risk 2.8; 95% confidence interval 1.2-6.9; p=0.042) to suffer from a future clinical event. The area under the curve (AUC) was 0.71 (95% confidence interval 0.51-0.86; p=0.046). After 3 days, patients with CT-proET-1 levels >/=57 pmol/L were 6 times more likely (relative risk 5.9; 95% confidence interval 0.9-40.4; p=0.036) to suffer from a future clinical event. The AUC was 0.76 (95% confidence interval 0.55-0.90; p=0.015). Conclusions: Elevatedlevels of MR-proADM and CT-proET-1 during the acute phase of myocardial infarction may predict an adverse long-term clinical outcome. Clin Chem Lab Med 2008;46:204-11.
机译:摘要背景:中部肾上腺髓质素原(MR-proADM)和内皮素-1已被证明可预测急性心肌梗死的死亡率。然而,两种生物标志物在预测急性心肌梗死后长期临床事件中的预后价值尚不清楚。方法:在一项前瞻性研究中,招募了30例患有急性ST抬高型心肌梗塞或非ST抬高型心肌梗塞的患者。 MR-proADM和CT-pro-theothelin-1(CT-proET-1)的测量是在急性心肌梗死后的第2、3天和4个月时进行的。从第4个月到第10个月期间,记录了长期的临床事件(例如反复发作的心肌梗塞,经皮腔内冠状动脉成形术,主动脉-冠状静脉搭桥术或心源性休克)。结果:MR-proADM和CT-proET-1均能够区分具有后续长期临床事件(n = 11)与无长期临床事件(n = 19)的患者。在急性心肌梗死时,事件组的中位MR-proADM水平为0.69 nmol / L,而无事件组为0.59 nmol / L(p = 0.036)。 3天后仍观察到差异(事件组中位数为0.66nmol / L;非事件组中位数为0.57nmol / L; p = 0.022)。因此,事件组的CT-proET-1中位值为72.9 pmol / L,而急性心肌梗死后3天无事件组(p = 0.009)的患者中位值为54.4 pmol / L。在急性期,MR-proADM水平> / = 0.67 nmol / L的患者未来发生临床事件的可能性高3倍(相对风险2.8; 95%置信区间1.2-6.9; p = 0.042)。曲线下面积(AUC)为0.71(95%置信区间0.51-0.86; p = 0.046)。 3天后,CT-proET-1水平> / = 57 pmol / L的患者未来发生临床事件的可能性高6倍(相对风险5.9; 95%置信区间0.9-40.4; p = 0.036)。 AUC为0.76(95%置信区间0.55-0.90; p = 0.015)。结论:心肌梗死急性期MR-proADM和CT-proET-1升高可能预示了不良的长期临床结果。 Clin Chem Lab Med 2008; 46:204-11。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号